The DNA repair pathway as a therapeutic target to synergize with trastuzumab deruxtecan in HER2-targeted antibody-drug conjugate-resistant HER2-overexpressing breast cancer.
Jangsoon LeeKumiko KidaJiwon KohHuey LiuGaniraju C ManyamYoung Jin GiDileep R RampaAsha S MultaniJing WangGitanjali JayachandranDae-Won LeeJames M ReubenAysegul SahinLei HuoDebu TripathySeock-Ah ImNaoto T UenoPublished in: Journal of experimental & clinical cancer research : CR (2024)
The DNA repair pathways contribute to HER2-directed ADC resistance. Our data justify exploring the combination treatment of T-DXd with DNA repair-targeting drugs to treat HER2-directed ADC-resistant HER2+ breast cancer in clinical trials.
Keyphrases
- dna repair
- dna damage
- cancer therapy
- clinical trial
- dna damage response
- diffusion weighted imaging
- diffusion weighted
- epidermal growth factor receptor
- electronic health record
- drug delivery
- randomized controlled trial
- oxidative stress
- magnetic resonance
- magnetic resonance imaging
- breast cancer risk
- combination therapy
- young adults
- phase ii
- contrast enhanced
- tyrosine kinase
- phase iii